top of page
Embryonic Stem Cells

Who We Are


We’re a young and talented group of scientists and innovators with a groundbreaking idea designed to contribute towards a better tomorrow. At Inspira, we have a relentless focus on what is possible, we thrive on experimentation and collaboration, and we embrace ideas that break with convention. Contact us today for more information or a press pack.

About: About Us
Female Scientist

Our Technology

Our IPX formulations are based on proprietary plant extracts that we have in-licensed for use in the field of respiratory disease.  These extracts, have previously been successfully investigated in patients suffering from various hard-to heal wounds and skin disorders.  They have shown superior activity compared to leading enzymatic agents for treating chronic skin conditions. 

SARS-CoV-2 particles are coated in a protein envelope that plays key roles in structural integrity and pathogenesis.  Of particular importance is the viral spike protein (S protein), multiple copies of which protrude from the viral envelope.  These spikes are recognised and bound by specific (‘ACE2’) host cell surface receptors, and this interaction facilitates infection of the cell by the virus. Much progress has been made in the understanding of this process, and methods to interfere with the interaction are being actively explored to reduce virus infectivity.

In 2021, Inspira commenced preclinical research at the University of Oxford to determine the virucidal activity of our IPX formulations using the live SARS-CoV-2 virus.  

Our IPX formulations have displayed promising virucidal activity against SARS-CoV-2 and we believe they have the ability to rapidly degrade or destroy the SARS-CoV-2 viral spike proteins.  Our work will now focus on testing and developing our technology to prepare for human trials. 

In 2021 we also commenced proof-of-concept research to test our IPX formulations against bacterial biofilms.  Our research focusses on the inhibition and disruption of biofilm formation in the lungs, which can be difficult to treat as some biofilms are antibiotic resistant and higher drug doses are often needed to reach sites of infection (particularly with lower respiratory tract infections).  Results so far have been very encouraging and we are excited to be rapidly advancing this research.

About: Our Technology
bottom of page